Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.180 +0.210 (+7.07%)
Streaming Delayed Price Updated: 11:15 AM EDT, May 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 Next >
TechMediaBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Advances AI Voice-Based Intoxication Detection as Real-Time Diagnostics Market Expands
Via Investor Brand Network
Topics Artificial Intelligence
The Future of Intoxication Detection May Be in Your Voice
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Recursion Reports First Quarter Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th
Company to host public (L)earnings call on August 5th at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The Future of Intoxication Detection May Be in Your Voice
From BioMedWire
Via GlobeNewswire
News headline image
Recursion Announces Board Transition
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6
Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform
From Citeline
Via GlobeNewswire
News headline image
Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Stocks Under $5 to Watch Now: LRMR, RXRX, NDRA, BTQ, CDIO Watch Now!
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
Via AB Newswire
Topics Artificial Intelligence
News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces CEO Transition Plan to Drive Next Phase of Growth
Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and President 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th
Company to host public (L)earnings call on November 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMT 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:RLYB),(NASDAQ:BTAI),(NYSE:PFE) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update
Company shares partnership and clinical updates including $7 million Sanofi milestone and more information on patient populations for REC-1245 (RBM39) and REC-617 (CDK7) 
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.